This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Oncoinvent Announces Positive 2H 2025 Results
Business Earnings Report

Oncoinvent Announces Positive 2H 2025 Results

Analysis based on 7 articles · First reported Feb 26, 2026 · Last updated Feb 26, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive results and strategic advancements from Oncoinvent are expected to have a positive impact on its stock price and investor confidence. The merger with BerGenBio and uplisting to the Oslo Stock Exchange also enhance Oncoinvent's market visibility and financial foundation.

Biotechnology Pharmaceuticals
Event Summary

Oncoinvent, a biotech company, announced its second half 2025 results, highlighting significant progress in its clinical programs for Radspherin, a radiopharmaceutical for cancer treatment. Key achievements include positive final data from the Phase 1 trial of Radspherin in ovarian cancer, publication of these results, and presentation of safety and efficacy data for colorectal cancer. Corporately, Oncoinvent completed a merger with BerGenBio, successfully uplisted to the Oslo Stock Exchange, and raised NOK 130 million in equity. The company also appointed Dr. Ramzi Amri as Chief Financial Officer. These developments are seen as strengthening Oncoinvent's financial foundation ahead of a planned Phase 2 interim readout.

Key Actions
100 Oncoinvent announced positive second half 2025 results
90 Oncoinvent completed merger BerGenBio
85 Oncoinvent uplisted to Oslo Stock Exchange Oslo Stock Exchange
80 Oncoinvent progressed Radspherin Phase 2 trial in ovarian cancer
80 Oncoinvent raised NOK 130 million in equity
75 Oncoinvent reported positive final data from Phase 1 Trial of Radspherin
60 Oncoinvent appointed Chief Financial Officer Ramzi Amri
Entities Involved
priv
Oncoinvent
Oncoinvent announced positive second half 2025 results, including advancements in its Radspherin clinical programs for ovarian and colorectal cancer. The company also completed a merger with BerGenBio, uplisted to the Oslo Stock Exchange, and raised NOK 130 million in equity, strengthening its financial position.
Importance 100 Sentiment 50
per
Øystein Soug
As CEO of Oncoinvent, Øystein Soug provided commentary on the company's productive second half of 2025, highlighting solid advances in clinical programs and important corporate and financial milestones.
Importance 70 Sentiment 40
stock
BerGenBio
BerGenBio completed a merger with Oncoinvent, which resulted in Oncoinvent's uplisting to the Oslo Stock Exchange.
Importance 30 Sentiment 0
exch
Oslo Stock Exchange
Oncoinvent successfully uplisted to the Oslo Stock Exchange following its merger with BerGenBio.
Importance 20 Sentiment 0
per
Ramzi Amri
Dr. Ramzi Amri was appointed as Chief Financial Officer of Oncoinvent.
Importance 10 Sentiment 0
cnt
Norway
Norway is the location where Oncoinvent is based and where the Oslo Stock Exchange operates.
Importance 5 Sentiment 0
Relationships
Øystein Soug related ↔ Oncoinvent
Ramzi Amri related ↔ Oncoinvent
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.